S&P Futures
4,072.50 -17.50 (-0.43%) Dow Futures
34,001.00 -155.00 (-0.45%) Nasdaq Futures
12,108.00 -44.00 (-0.36%) Russell 2000 Futures
1,932.10 -7.30 (-0.38%) Crude Oil
79.12 +0.25 (+0.32%) Gold
1,942.10 -3.20 (-0.16%)
G1 THERAPEUTICS DL-,0001 (G1H.BE)
Chart Events
Performance Outlook
| Previous Close | 7.35 |
| Open | 7.32 |
| Bid | 7.06 x 0 |
| Ask | 7.56 x 0 |
| Day's Range | 7.31 - 7.32 |
| 52 Week Range | 3.67 - 17.36 |
| Volume | |
| Avg. Volume | 15 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Feb 21, 2023 - Feb 27, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
G1 Therapeutics to Participate in the Virtual 2023 B. Riley Securities 3rd Annual Oncology Conference
RESEARCH TRIANGLE PARK, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that on January 19th, 2023, at 11:30 AM EST, G1’s Chief Executive Officer Jack Bailey will provide a corporate presentation during the virtual 2023 B. Riley Securities 3rd Annual Oncology Conference. The webcast of the event will be accessible on the Events & Presentations page of http://www.g1therapeutics.com. About G1 TherapeuticsG1 Therapeu
- GlobeNewswire
G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib
- Initial Results from Pivotal Phase 3 PRESERVE 1 Trial in Colorectal Cancer Expected in February 2023; Positive Results Would Initiate Regulatory Interactions for Label Expansion - - Five Clinical Trials with Data Readouts in 2023 Will Evaluate Trilaciclib On-Target Effects of Myeloprotection and Enhanced Immune Function with Potential for Improved Efficacy Outcomes (Progression Free (PFS) and Overall Survival (OS)) - - Trilaciclib’s Potential Synergistic Effects with Chemotherapy, Antibody Dru
- Benzinga
G1 Therapeutics Reveals An Early Cut Data From Bladder Cancer Trial
G1 Therapeutics Inc (NASDAQ: GTHX) provided an initial update on the PRESERVE 3 Phase 2 study of first-line platinum-based chemotherapy and maintenance therapy with avelumab, administered alone, or in combination with trilaciclib, in patients with untreated, locally advanced or metastatic urothelial carcinoma (mUC). Additional safety and efficacy data, including the primary endpoint of progression-free survival (PFS), are anticipated in the middle of 2023. The confirmed objective response rate (
